Home › Companies › CYTOSORBENTS CORP. › 2024-2025
At CYTOSORBENTS CORP.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 55 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 157 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CYTOSORBENTS CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CYTOSORBENTS CORP.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 12, 2025: 7 items on CYTOSORBENTS CORP.’s Form 8-K, filed June 13, 2025: 7 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore CYTOSORBENTS CORP. in the interactive database Compare manager voting policies
These tallies are CYTOSORBENTS CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Phillip P. Chan | 21,479,032 | 1,107,546 | 64,976 | -- | 17,419,927 | 95% | Not verified | — |
| Elect Director: Dr. Edward R. Jones | 19,790,544 | 2,791,100 | 69,910 | -- | 17,419,927 | 88% | Not verified | — |
| Elect Director: Michael Bator | 19,687,559 | 2,705,796 | 258,199 | -- | 17,419,927 | 88% | Not verified | — |
| Elect Director: Alan D. Sobel | 19,313,170 | 3,319,370 | 19,014 | -- | 17,419,927 | 85% | Not verified | — |
| Elect Director: Jiny Kim | 21,388,189 | 913,647 | 349,718 | -- | 17,419,927 | 96% | Not verified | — |
| 2. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K; and | 18,189,951 | 1,720,512 | 2,741,091 | -- | 17,419,927 | 91% | Not verified | — |
| 3. The ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 39,485,868 | 553,680 | 31,933 | -- | -- | 99% | Not verified | — |
Source: CYTOSORBENTS CORP., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.
Each item below shows how the 55 asset managers that disclosed a CYTOSORBENTS CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Alan D. Sobel, CPA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Alan D. Sobel”): 19,313,170 for, 3,319,370 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 1,962,328 for, 710,154 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 678,907 | 0 | 0 | Against |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 22,540 | 0 | 0 | Against |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 8,707 | 0 | 0 | Against |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Edward R. Jones, MD, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Dr. Edward R. Jones”): 19,790,544 for, 2,791,100 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 1,962,328 for, 710,154 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 678,907 | 0 | 0 | Against |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 22,540 | 0 | 0 | Against |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 8,707 | 0 | 0 | Against |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Jiny Kim, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Jiny Kim”): 21,388,189 for, 913,647 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 2,672,482 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 678,907 | 0 | 0 | 0 | For |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 22,540 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Michael G. Bator, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Michael Bator”): 19,687,559 for, 2,705,796 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 1,962,328 for, 710,154 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 678,907 | 0 | 0 | Against |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 22,540 | 0 | 0 | Against |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 8,707 | 0 | 0 | Against |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Phillip P. Chan, MD, PhD
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Dr. Phillip P. Chan”): 21,479,032 for, 1,107,546 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 2,672,482 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 678,907 | 0 | 0 | 0 | For |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 22,540 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K.
CYTOSORBENTS CORP.’s own tally for this item (“2. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K; and”): 18,189,951 for, 1,720,512 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 678,907 | 0 | 0 | 0 | For |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 22,540 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 2,672,482 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AVENIR CORP | 4,762,614 | 0 | 0 | 0 | For |
| Skylands Capital, LLC | 2,952,815 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,479,035 | 0 | 0 | 0 | For |
| BlackRock | 357,911 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 172,649 | 0 | 0 | 0 | For |
| STRS OHIO | 123,463 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 113,089 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 82,337 | 0 | 0 | 0 | For |
| Northern Trust | 63,550 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 48,000 | 0 | 0 | 0 | For |
| Renaissance | 47,300 | 0 | 0 | 0 | For |
| State Street | 40,087 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 38,527 | 0 | 0 | 0 | For |
| SEI | 35,110 | 0 | 0 | 0 | For |
| COUNTRY CLUB BANK | 15,225 | 0 | 0 | 0 | For |
| Vanguard | 13,865 | 0 | 0 | 0 | For |
| SECURITY NATIONAL TRUST CO | 12,200 | 0 | 0 | 0 | For |
| Chicago Partners Investment Group LLC | 11,237 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 11,000 | 0 | 0 | 0 | For |
| COMMERCE BANK | 8,764 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 6,537 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 5,330 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 3,640 | 0 | 0 | 0 | For |
| BAILARD, INC. | 2,792 | 0 | 0 | 0 | For |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2,082 | 0 | 0 | 0 | For |
Institutional-manager reports, all 48 managers: 10,422,518 for, 1,452 against, 250 unknown. Showing the 25 largest; every one is in the interactive database (link above).
99% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of WithumSmith+Brown, PC as CytoSorbents Corporation's independent auditors to audit CytoSorbents Corporation's financial statements for the fiscal year ending December 31, 2025.
CYTOSORBENTS CORP.’s own tally for this item (“3. The ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 39,485,868 for, 553,680 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 2,672,482 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,816,686 | 0 | 0 | 0 | For |
| Neuberger Berman | 678,907 | 0 | 0 | 0 | For |
| Fidelity | 110,926 | 0 | 0 | 0 | For |
| Victory Capital | 27,785 | 0 | 0 | 0 | For |
| Morgan Stanley | 22,540 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| Jackson National | 6,686 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 62,610,376 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.90% |
| 2 | Neuberger Berman | 1.08% |
| 3 | Fidelity | 0.18% |
| 4 | Victory Capital | 0.04% |
| 5 | Morgan Stanley | 0.04% |
| 6 | TRUST FOR PROFESSIONAL MANAGERS | 0.01% |
| 7 | Jackson National | 0.01% |
| 8 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | AVENIR CORP | 7.61% |
| 2 | Skylands Capital, LLC | 4.72% |
| 3 | Neuberger Berman | 2.36% |
| 4 | BlackRock | 0.57% |
| 5 | CIBC Private Wealth Group LLC | 0.28% |
| 6 | STRS OHIO | 0.20% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.18% |
| 8 | Granahan Investment Management, LLC | 0.13% |
| 9 | Northern Trust | 0.10% |
| 10 | STIFEL NICOLAUS & CO INC \MO\ | 0.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| AVENIR CORP | 8.35% | 13G |
| ROKK LLC | 6.41% | DEF14A |
| Thomas A. Satterfield, Jr. | 6.39% | 13G |
| Avenue Capital Management II, L.P. | 6.00% | 13G |
| Aventir Corporation | 4.94% | DEF14A |
| Skylands Capital, LLC | 4.80% | 13G |
| Vanguard Group | 3.11% | 13F |
| Phillip P. Chan, MD, PhD | 3.09% | DEF14A |
| Vincent J. Capponi, MS | 2.73% | DEF14A |
| BlackRock | 1.00% | 13F |
Percentages above are of 62,610,376 shares outstanding, as reported by CYTOSORBENTS CORP. on its Form 10-Q dated May 13, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTOSORBENTS CORP.’s 10-Q dated May 13, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CYTOSORBENTS CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).
proxyvotesnow.com, “CYTOSORBENTS (CTSO) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytosorbents-corp/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.